Sign in
CompletedPhase 2/3

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

Key facts

Who runs it
Biohaven Pharmaceuticals, Inc.
Where
Ann Arbor, Atlanta, Baltimore, Boston, Chicago, Dallas, Denver, Gainesville, Houston, Long Beach, Los Angeles, New York, Phoenix, Rochester, San Francisco, and Tampa, United StatesSee the 18 sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
141 people enrolled
Started
15 Dec 2016
Ended
20 Sept 2024
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Troriluzole
  • Placebo
Record updated
8 October 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participants with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10
  • Ability to ambulate 8 meters without assistance (canes and other devices allowed)
  • Screening total Scale for the Assessment and Rating of Ataxia (SARA) score ≥8
  • Score of ≥ 2 on the gait subsection of the SARA
  • Determined by the investigator to be medically stable at baseline/randomization and must be physically able and expected to complete the trial as designed

Who cannot take part

  • Any medical condition other than one of the hereditary ataxias specified in the inclusion criteria that could predominantly explain or contribute significantly to the participants symptoms of ataxia
  • Clinical history of stroke
  • Active liver disease or a history of hepatic intolerance to medications that in the investigator's judgment, is medically significant
  • Mini Mental State Exam (MMSE) score < 24
  • SARA total score of > 30 points at screening

Where in United States

  • University of MichiganAnn Arbor, United States
  • Emory UniversityAtlanta, United States
  • Johns Hopkins UniversityBaltimore, United States
  • Harvard University (Beth Israel Deaconess Medical Center)Boston, United States
  • Harvard University Massachusetts General HospitalBoston, United States
  • Northwestern UniversityChicago, United States
  • University of ChicagoChicago, United States
  • University of Texas, SouthwesternDallas, United States
  • University of Colorado DenverDenver, United States
  • University of FloridaGainesville, United States
  • Houston Methodist Research CenterHouston, United States
  • CNS TrialLong Beach, United States
  • University of California, Los AngelesLos Angeles, United States
  • Columbia UniversityNew York, United States
  • St. Joseph's Hospital and Medical CenterPhoenix, United States
  • University of Rochester Medical CenterRochester, United States
  • University of California San FranciscoSan Francisco, United States
  • University of South FloridaTampa, United States

About the trial

What the trial wants to find out

The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).

The 4 groups in the trial

  • Troriluzole - Randomization PhaseTreatment being tested

    Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.

    Treatment: Troriluzole

  • Placebo - Randomization PhasePlacebo, for comparison

    Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.

    Treatment: Placebo

  • Troriluzole/Troriluzole - OLE (Open Label Extension) PhaseTreatment being tested

    Participants received Troriluzole 140 mg capsules orally QD for 48 weeks in the extension period and were allowed to participate in 288 weeks for expanded extension phase, for a total of 336 weeks of open-label treatment.

    Treatment: Troriluzole

  • Placebo/Troriluzole - OLE PhaseTreatment being tested

    Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks in the extension period and were allowed to participate in 288 weeks for expanded extension phase, for a total of 336 weeks of open-label treatment.

    Treatment: Placebo and Troriluzole

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia
Record updated
8 October 2025